ArticleJCO precision oncology2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.
Abstract read
In one paragraph
Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer.Cancer research communications · 2026Article
- ImmunoNX: a robust bioinformatics workflow to support personalized neoantigen vaccine trials.ArXiv · 2025Article
- Review
- Personalizing DNA Cancer Vaccines.Journal of personalized medicine · 2025Review
- Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.Journal of personalized medicine · 2025Review
- Article
- Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability.Human cell · 2025Article
- Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.Oncotarget · 2025Article
- Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.Clinical proteomics · 2024Article
- The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.Cancers · 2024Review
- Article
- Case report:Frontiers in oncology · 2023Article
- Theranostic nanoparticles for detection and treatment of pancreatic cancer.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Daniel A KingNorthwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY.ORCID 0000-0001-6451-712X
Amber R SmithXilis Corporation, Durham, NC.
Gino PinedaStanford Cancer Institute, Stanford, CA.ORCID 0000-0003-4978-1103
Michitaka NakanoDepartment of Medicine, Divisions of Hematology and Oncology, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-1049-5791
Flavia MicheliniMemorial Sloan Kettering Cancer Center, NY, NY.ORCID 0000-0002-3727-4887
S Peter GoedegebuureDepartment of Surgery, Washington University School of Medicine in St Louis, St Louis, MO.
Sheeno ThyparambilMprobe, Inc, Rockville, MD.
Wei-Li LiaoMprobe, Inc, Rockville, MD.
Aaron McCormickDepartment of Medicine, Divisions of Hematology and Oncology, Stanford University School of Medicine, Stanford, CA.
Jihang JuDepartment of Medicine, Divisions of Hematology and Oncology, Stanford University School of Medicine, Stanford, CA.
Michele CioffiCornell University, School of Medicine, New York, NY.ORCID 0000-0003-4180-5369
Xiuli ZhangDepartment of Surgery, Washington University School of Medicine in St Louis, St Louis, MO.
Jasreet HundalDepartment of Surgery, Washington University School of Medicine in St Louis, St Louis, MO.
Malachi GriffithDepartment of Medicine, Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-6388-446X
Carla GrandoriSEngine Precision Medicine, Seattle, WA.
Maddy PollastroSEngine Precision Medicine, Seattle, WA.
Rachele RosatiSEngine Precision Medicine, Seattle, WA.
Astrid MargossianSEngine Precision Medicine, Seattle, WA.
Payel ChatterjeeSEngine Precision Medicine, Seattle, WA.
Trevor AingeSEngine Precision Medicine, Seattle, WA.
Marta FloryDepartment of Radiology, Stanford University, Stanford, CA.
Paolo OcampoPersonalized Healthcare, Genentech, Inc, South San Francisco, CA.
Lee-May ChenDepartment of Gynecologic Oncology, University of California at San Francisco, San Francisco, CA.
George A PoultsidesDepartment of Surgery, Section of Surgical Oncology, Stanford University, Stanford, CA.
Ari D BaronDivision of Hematology Oncology, California Pacific Medical Center, San Francisco, CA.
Daniel T ChangDepartment of Radiation Oncology, Stanford Cancer Institute, Stanford, CA.ORCID 0000-0003-2760-1554
Joseph M HermanDepartment of Radiation Oncology and Northwell Health Cancer Institute, Lake Success, NY.
William E GillandersDepartment of Surgery, Washington University School of Medicine in St Louis, St Louis, MO.
Haeseong ParkDepartment of Medicine, Division of Oncology, Washington University School of Medicine in St Louis.ORCID 0000-0002-3430-8463
William A HoosxCures Inc, Oakland, CA.
Mike NicholsIndependent Clinician, Saratoga, CA.
George A FisherStanford Cancer Institute, Stanford, CA.ORCID 0000-0002-6828-3938
Calvin J KuoStanford Cancer Institute, Stanford, CA.ORCID 0000-0002-7427-5985
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MUCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Collin M Blakely · 2017 to 2026
$12.9MWashington University SPORE in Pancreatic CancerP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, WILLIAM G HAWKINS · 2023 to 2026
$10.7MOrganoid-based Discovery of Oncogenic Drivers and Treatment Resistance MechanismsU01CA217851 · NCI · STANFORD UNIVERSITY · PI CURTIS, CHRISTINA N, JI, HANLEE P · 2017 to 2021
$4.7MAn Academic-Industry Partnership to Advance Functional Genomics for Personalized Oncology.R01CA214428 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KEMP, CHRISTOPHER J · 2018 to 2022
$3.0MInformatics tools for identification, prioritization and clinical application of neoantigensU01CA248235 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2020 to 2022
$1.3MNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA272213NCI NIH HHS R01 CA214428NCI NIH HHS U01 CA217851NCI NIH HHS U01 CA248235NCI NIH HHS U54 CA224081
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenocarcinomaPancreatic NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.